Table 4.
Association between antihypertensive use and fatigue of COVID-19 patients with hypertension comorbidity.
| Unadjusted | Adjusteda | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Total patients | Fatigue = 0 | Fatigue = 1 | OR | 95% CI | P value | OR | 95% CI | P value | |
| Cohort C, n (%) | 617 | 340 | 277 | |||||||
| No use | 59 (9.6) | 26 (7.6) | 33 (11.9) | Ref. | Ref. | Ref. | Ref. | |||
| ARB | 139 (22.5) | 88 (25.9) | 51 (18.4) | 0.457 | 0.246–0.848 | 0.018 | 0.643 | 0.457–0.906 | 0.012 | |
| ACEI | 43 (7) | 22 (6.5) | 21 (7.6) | 0.752 | 0.342–1.655 | 0.549 | 0.956 | 0.709–1.289 | 0.768 | |
| Thiazide | 34 (5.5) | 24 (7.1) | 10 (3.6) | 0.328 | 0.134–0.807 | 0.018 | 0.817 | 0.61–1.095 | 0.177 | |
| BB | 95 (15.4) | 50 (14.7) | 45 (16.2) | 0.709 | 0.369–1.362 | 0.324 | 0.951 | 0.815–1.11 | 0.525 | |
| CCB | 423 (68.6) | 233 (68.5) | 190 (68.6) | 0.642 | 0.371–1.112 | 0.126 | 0.64 | 0.36–1.14 | 0.13 | |
| Older than 65 years from cohort C, n (%) | 293 | 154 | 139 | |||||||
| No use | 26 (8.9) | 10 (6.5) | 16 (11.5) | Ref. | Ref. | Ref. | Ref. | |||
| ARB | 71 (24.2) | 44 (28.6) | 27 (19.4) | 0.384 | 0.152–0.966 | 0.064 | 0.518 | 0.278–0.965 | 0.038 | |
| ACEI | 19 (6.5) | 9 (5.8) | 10 (7.2) | 0.694 | 0.210–2.301 | 0.761 | 0.671 | 0.374–1.204 | 0.181 | |
| Thiazide | 22 (7.5) | 15 (9.7) | 7 (5) | 0.292 | 0.088–0.964 | 0.049 | 0.637 | 0.382–1.06 | 0.083 | |
| BB | 50 (17.1) | 23 (14.9) | 27 (19.4) | 0.734 | 0.279–1.928 | 0.628 | 0.887 | 0.678–1.162 | 0.385 | |
| CCB | 201 (68.6) | 106 (68.8) | 95 (68.3) | 0.56 | 0.242–1.294 | 0.212 | 0.475 | 0.186–1.209 | 0.118 | |
aFully adjusted model includes the following covariates: age, gender, baseline of blood pressure (including SBP and DBP), and coexisting medical conditions (including chronic heart, lung, renal, liver, and cerebrovascular disease, diabetes, and cancer).